Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. Its biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. The company's discovery services provide the tools and testing methods for companies and researchers to identify new molecular-based biomarkers for disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGIX
CUSIPN/A
Phone201-528-9200
Debt
Debt-to-Equity Ratio0.03
Current Ratio0.92
Quick Ratio0.92
Price-To-Earnings
Trailing P/E Ratio-1.26
Forward P/E Ratio-2.16
P/E GrowthN/A
Sales & Book Value
Annual Sales$29.12 million
Price / Sales0.95
Cash FlowN/A
Price / CashN/A
Book Value$0.97 per share
Price / Book1.02
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-20,880,000.00
Net Margins-52.87%
Return on Equity-77.26%
Return on Assets-38.54%
Miscellaneous
Employees245
Outstanding Shares27,750,000
Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions
What is Cancer Genetics' stock symbol?
Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."
How were Cancer Genetics' earnings last quarter?
Cancer Genetics Inc (NASDAQ:CGIX) released its quarterly earnings data on Tuesday, May, 15th. The medical research company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.03. The medical research company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.20 million. Cancer Genetics had a negative return on equity of 77.26% and a negative net margin of 52.87%. View Cancer Genetics' Earnings History.
What price target have analysts set for CGIX?
4 analysts have issued 12-month price objectives for Cancer Genetics' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Cancer Genetics' stock price to reach $5.00 in the next year. View Analyst Ratings for Cancer Genetics.
What are Wall Street analysts saying about Cancer Genetics stock?
Here are some recent quotes from research analysts about Cancer Genetics stock:
- 1. According to Zacks Investment Research, "Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey. " (5/14/2018)
- 2. Maxim Group analysts commented, "We are downgrading CGIX to Hold, from Buy and removing our price target following disappointing 4Q revenues, an increase in bad debt expense which was a surprise that leaves us with some concerns around the company’s ability to collect account receivables related to acquired testing platforms and/ or companies, and in our view, a lack of strategic direction of the company. 4Q17 revenue of $7.5M, up 4% y/y compared to the consensus estimate of $9.2M. Operating expenses in 4Q17 rose 82% and included $4.4M in bad debt expense." (4/3/2018)
Are investors shorting Cancer Genetics?
Cancer Genetics saw a decline in short interest in May. As of May 31st, there was short interest totalling 565,972 shares, a decline of 38.5% from the May 15th total of 919,865 shares. Based on an average trading volume of 207,962 shares, the short-interest ratio is currently 2.7 days. Currently, 2.5% of the company's stock are sold short. View Cancer Genetics' Current Options Chain.
Who are some of Cancer Genetics' key competitors?
Who are Cancer Genetics' key executives?
Cancer Genetics' management team includes the folowing people:
- Mr. John A. Roberts, Interim CEO & COO (Age 59)
- Dr. Raju S. K. Chaganti, Founder & Director (Age 85)
- Mr. Igor Gitelman CPA, MBA, Chief Accounting Officer (Age 42)
- Mr. Cory Hickmon, VP of Bus. Devel. and Director of National Clinical Sales
- Ms. Molly Lukes PHR, SHRM-CP, VP of HR
Has Cancer Genetics been receiving favorable news coverage?
Media coverage about CGIX stock has been trending positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cancer Genetics earned a news sentiment score of 0.25 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 47.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Cancer Genetics' major shareholders?
Cancer Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.22%). Company insiders that own Cancer Genetics stock include Edward J Sitar, Geoffrey E Harris, Igor Gitelman, John A Roberts and John Pappajohn. View Institutional Ownership Trends for Cancer Genetics.
Which institutional investors are selling Cancer Genetics stock?
How do I buy shares of Cancer Genetics?
Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cancer Genetics' stock price today?
One share of CGIX stock can currently be purchased for approximately $0.9917.
How big of a company is Cancer Genetics?
Cancer Genetics has a market capitalization of $28.58 million and generates $29.12 million in revenue each year. The medical research company earns $-20,880,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Cancer Genetics employs 245 workers across the globe.
How can I contact Cancer Genetics?
Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected]
MarketBeat Community Rating for Cancer Genetics (CGIX)
MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote "Outperform" if you believe CGIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
